Jabbit

Home / Peptides / KPV

Research review · Sources checked October 17, 2026

KPV: what the research shows

KPV (lysine-proline-valine) is the last three amino acids of the hormone alpha-MSH. It is not an FDA-approved drug, and FDA reports no human exposure data for it by any route.[1][2]

What the animal research shows

KPV has anti-inflammatory effects in rodents from several independent labs. In mice, KPV in drinking water reduced chemically induced colitis, apparently after being carried into gut cells by the PepT1 transporter.[3][4][5] It does not appear to act through melanocortin receptors, and FDA says its molecular targets remain unknown.[6][1]

Human data

No published trial has given KPV to people.[1] A related dimer, CZEN-002, was tested as a vaginal gel in an open-label study of 20 women with yeast infections in 2003–2004; no journal publication followed.[7] Plain KPV does not pass through intact human skin in lab tests.[8]

Regulatory status

KPV was nominated to FDA as a 0.1% topical cream for wounds and inflammatory skin conditions; the nomination was withdrawn and FDA reviewed it on its own initiative, recommending against the compounding list. In July 2026 FDA’s advisory committee voted 8 to 6, with 1 abstention, in favor.[1][9] An FDA peptide compounding policy went to the White House for review on October 14, 2026.[10]

What is not known

There are no human pharmacokinetic data, no standard toxicity studies and no established human dose.[1] For the full paper trail, including the 1991 patent and dose math, see our teardown below.

References

  1. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing document: KPV-related bulk drug substances (KPV free base and KPV acetate), for the July 23–24, 2026 meeting. Sections on the nomination (0.1% cream or gel, topical, for wound healing and inflammatory conditions), characterization, historical use (“No published studies were found in which … drug products containing KPV … were used in humans”; outsourcing facilities reported none compounded January 2017 to June 2025), online promotion, pharmacology (“the molecular targets … remain unknown”), absent pharmacokinetic and toxicity studies, FAERS search through December 3, 2025, and FDA’s conclusion (“lack of any human data … via any route of administration, including lack of information to assess immunogenicity or aggregation”). https://www.fda.gov/media/193346/download. Checked October 17, 2026.
  2. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2). Content current as of April 22, 2026. KPV appears in the table of substances nominated but withdrawn: “FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration.” https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks. Checked October 17, 2026.
  3. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. doi:10.1053/j.gastro.2007.10.026. PMID 18061177 (KPV “added to drinking water” in DSS and TNBS colitis). https://pubmed.ncbi.nlm.nih.gov/18061177/. Checked October 17, 2026.
  4. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. doi:10.1002/ibd.20334. PMID 18092346. https://pubmed.ncbi.nlm.nih.gov/18092346/. Checked October 17, 2026.
  5. Viennois E, Ingersoll SA, Ayyadurai S, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol. 2016;2(3):340-357. doi:10.1016/j.jcmgh.2016.01.006. PMID 27458604; full text PMC4957955 (“100 μmol/L KPV in their drinking water”). https://pubmed.ncbi.nlm.nih.gov/27458604/. Checked October 17, 2026.
  6. Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631-637. doi:10.1124/jpet.103.051623. PMID 12750433. https://pubmed.ncbi.nlm.nih.gov/12750433/. Checked October 17, 2026.
  7. Zengen, Inc. press release via EurekAlert!, May 25, 2004: Phase I/II results for CZEN-002 in vulvovaginal candidiasis (open-label, non-randomized; 20 enrolled, 17 completed; 88.2% negative by KOH test and 87.5% by culture; no severe adverse reactions; plasma levels undetectable or below the limit of quantitation; Lipton cited earlier trials “completed in China”; Phase IIb planned in Europe and Canada). https://www.eurekalert.org/news-releases/796451. Checked October 17, 2026.
  8. Pawar K, Kolli CS, Rangari VK, et al. Transdermal iontophoretic delivery of lysine-proline-valine (KPV) peptide across microporated human skin. J Pharm Sci. 2017;106(7):1814-1820. doi:10.1016/j.xphs.2017.03.017. PMID 28343991 (passive permeation below the detection limit of 0.01 μg/mL; 4.4 μg/cm²/h after microneedle treatment). https://pubmed.ncbi.nlm.nih.gov/28343991/. Checked October 17, 2026.
  9. Vote tallies from the July 2026 Pharmacy Compounding Advisory Committee meeting (KPV 8 yes, 6 no, 1 abstain): Holland & Knight, Peptides at a Crossroads, October 2026 https://www.hklaw.com/en/insights/publications/2026/10/peptides-at-a-crossroads-what-wellness-providers-need-to-know; MDside, The FDA advisory vote on six peptides, October 9, 2026 https://www.mdside.com/peptide-advisory-vote-what-happens-next/. Checked October 17, 2026.
  10. Office of Information and Regulatory Affairs (OMB). Pending EO 12866 Regulatory Review: Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94, received 10/14/2026; no conclusion listed when checked. https://www.reginfo.gov/public/do/eoDetails?rrid=1568964. Checked October 17, 2026.

This page summarizes published research and regulatory documents. It is not medical advice and does not recommend using, sourcing, or dosing any of these substances.